SCHEMBL335968

SCHEMBL335968

CCN(CC)c1ccc(C(=O)NC(c2cccc(C)c2)C(O)C(=O)Nc2ccc3nc(N)[nH]c3c2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.41
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
MMP8 P22894 2/20 0.39
MMP13 P45452 2/20 0.39
F9 P00740 1/20 0.38
F7 P08709 1/20 0.38
IKBKB O14920 1/20 0.38
DGAT1 O75907 1/20 0.38
LMNA P02545 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
GAA P10253 1/20 0.36
GBA1 P04062 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
POLB P06746 1/20 0.36
CNR2 P34972 1/20 0.36
ESRRG P62508 1/20 0.35
AURKA O14965 1/20 0.35
RPS6KB1 P23443 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335484 0.92 MAPT (0.43) MAPTMMP2MMP9MMP8MMP13
SCHEMBL336687 0.92 MAPT (0.39) MAPTF9F7IKBKBDGAT1
SCHEMBL336055 0.90 MAPT (0.46) MAPTF9F7IKBKBLMNA
SCHEMBL337002 0.88 MAPT (0.41) MAPTF9F7IKBKBLMNA
SCHEMBL335874 0.88 MAPT (0.39) MAPTMMP2MMP9MMP8MMP13
SCHEMBL335303 0.88 MAPT (0.40) MAPTF9F7IKBKBLMNA
SCHEMBL335191 0.87 MAPT (0.45) MAPTMMP2MMP9MMP8MMP13
SCHEMBL335848 0.86 MCHR1 (0.42) MAPTF9F7IKBKBSMN1; SMN2
SCHEMBL336083 0.86 F9 (0.41) MAPTF9F7IKBKBDGAT1
SCHEMBL335959 0.85 MAPT (0.41) MAPTF9F7IKBKBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 MAPT 3998/4885MMP2 424/4885MMP9 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.